Wordt geladen...
Treatment Challenges in Severe Eosinophilic Asthma: Differential Response to Anti-IL-5 and Anti-IL-5R Therapy
Severe asthma greatly affects patients’ quality of life. Major advances have occurred in the management of severe eosinophilic asthma the past few years due to the new targeted biological therapies. There are three anti-IL-5 mAbs, mepolizumab, reslizumab and benralizumab. Despite the different mecha...
Bewaard in:
| Gepubliceerd in: | Int J Mol Sci |
|---|---|
| Hoofdauteurs: | , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
MDPI
2021
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8069413/ https://ncbi.nlm.nih.gov/pubmed/33921360 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ijms22083969 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|